The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

We discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human hepatoma cell lines independently of the previously proposed HCV receptor CD81. Comparative binding studies using recombinant E2 from the most prevalent 1a and 1b genotypes revealed that E2 recognition by hepatoma cells is independent from the viral isolate, while E2–CD81 interaction is isolate specific. Binding of soluble E2 to human hepatoma cells was impaired by deletion of the hypervariable region 1 (HVR1), but the wild‐type phenotype was recovered by introducing a compensatory mutation reported previously to rescue infectivity of an HVR1‐deleted HCV infectious clone. We have identified the receptor responsible for E2 binding to human hepatic cells as the human scavenger receptor class B type I (SR‐BI). E2–SR‐BI interaction is very selective since neither mouse SR‐BI nor the closely related human scavenger receptor CD36, were able to bind E2. Finally, E2 recognition by SR‐BI was competed out in an isolate‐specific manner both on the hepatoma cell line and on the human SR‐BI‐transfected cell line by an anti‐HVR1 monoclonal antibody.

[1]  F. G. van der Goot,et al.  Raft membrane domains: from a liquid-ordered membrane phase to a site of pathogen attack. , 2001, Seminars in immunology.

[2]  K. Meyer,et al.  Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. , 2002, The Journal of infectious diseases.

[3]  Sobolev,et al.  Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions , 2000, Journal of viral hepatitis.

[4]  A. Oppenheim,et al.  Caveolar Endocytosis of Simian Virus 40 Is Followed by Brefeldin A-Sensitive Transport to the Endoplasmic Reticulum, Where the Virus Disassembles , 2002, Journal of Virology.

[5]  M. Vega,et al.  Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. , 1993, The Journal of biological chemistry.

[6]  D. Gómez-Coronado,et al.  CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[7]  M. Houghton,et al.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  V. Agnello,et al.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Ishii,et al.  Characterization of pseudotype VSV possessing HCV envelope proteins. , 2001, Virology.

[10]  T. Gojobori,et al.  Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization , 1998, Archives of Virology.

[11]  A. Meola,et al.  Binding of Hepatitis C Virus E2 Glycoprotein to CD81 Does Not Correlate with Species Permissiveness to Infection , 2000, Journal of Virology.

[12]  C. Enrich,et al.  Biochemical analysis of a caveolae‐enriched plasma membrane fraction from rat liver , 2000, Electrophoresis.

[13]  M. Mondelli,et al.  Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients , 1995, Journal of virology.

[14]  W. J. Johnson,et al.  Cellular Cholesterol Efflux Mediated by Cyclodextrins , 1996, The Journal of Biological Chemistry.

[15]  J. Hoofnagle,et al.  Therapy of Hepatitis C , 1995, Seminars in liver disease.

[16]  A Cerino,et al.  Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? , 2001, Antiviral research.

[17]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Lodish,et al.  Expression cloning of SR-BI, a CD36-related class B scavenger receptor. , 1994, The Journal of biological chemistry.

[19]  S. Emerson,et al.  Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Tall,et al.  High Density Lipoprotein (HDL) Particle Uptake Mediated by Scavenger Receptor Class B Type 1 Results in Selective Sorting of HDL Cholesterol from Protein and Polarized Cholesterol Secretion* , 2001, The Journal of Biological Chemistry.

[21]  K. Okita,et al.  A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization , 2001, Journal of viral hepatitis.

[22]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[23]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[25]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[26]  R. Bartenschlager,et al.  Novel cell culture systems for the hepatitis C virus. , 2001, Antiviral research.

[27]  Richard G. W. Anderson,et al.  Murine SR-BI, a High Density Lipoprotein Receptor That Mediates Selective Lipid Uptake, Is N-Glycosylated and Fatty Acylated and Colocalizes with Plasma Membrane Caveolae* , 1997, The Journal of Biological Chemistry.

[28]  S. Emerson,et al.  Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. , 2000, Virology.

[29]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Goldsmith,et al.  Association of the Caveola Vesicular System with Cellular Entry by Filoviruses , 2002, Journal of Virology.

[31]  M. Krieger,et al.  Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. , 2001, The Journal of clinical investigation.

[32]  W. J. Johnson,et al.  Cellular Cholesterol Efflux Mediated by Cyclodextrins (*) , 1995, The Journal of Biological Chemistry.

[33]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[34]  Anna Tramontano,et al.  Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross‐reacting with a large number of viral variants , 1998, The EMBO journal.

[35]  M. Houghton,et al.  Structure-Function Analysis of Hepatitis C Virus Envelope-CD81 Binding , 2000, Journal of virology.

[36]  G. Deléage,et al.  Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment , 2001, Journal of Virology.

[37]  Anna Tramontano,et al.  A model for the hepatitis C virus envelope glycoprotein E2 , 2000, Proteins.

[38]  R. Silverstein,et al.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.

[39]  J. Dubuisson,et al.  Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81 , 1999, Journal of Virology.

[40]  N. Kato,et al.  Hypervariable regions in the putative glycoprotein of hepatitis C virus. , 1991, Biochemical and biophysical research communications.

[41]  T. Liang,et al.  Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. , 2002, Virology.

[42]  A. Weiner,et al.  Sequence variation in hepatitis C viral isolates. , 1991, Journal of hepatology.

[43]  A. Meola,et al.  Monoclonal Antibodies with Broad Specificity for Hepatitis C Virus Hypervariable Region 1 Variants Can Recognize Viral Particles1 , 2001, The Journal of Immunology.

[44]  M. Esumi,et al.  Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro. , 2000, Virology.

[45]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[46]  J. Bergelson,et al.  Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Martínez-A,et al.  Membrane raft microdomains mediate lateral assemblies required for HIV‐1 infection , 2000, EMBO reports.

[48]  T. Kähne,et al.  Non-radioactive labelling and immunoprecipitation analysis of leukocyte surface proteins using different methods of protein biotinylation. , 1994, Journal of immunological methods.

[49]  Arvind H. Patel,et al.  Analysis of Antigenicity and Topology of E2 Glycoprotein Present on Recombinant Hepatitis C Virus-Like Particles , 2002, Journal of Virology.

[50]  L. Seeff,et al.  Hepatitis C: a brief clinical overview. , 2001, ILAR journal.

[51]  P. Borrow,et al.  Functional Characterization of Intracellular and Secreted Forms of a Truncated Hepatitis C Virus E2 Glycoprotein , 2000, Journal of Virology.